Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flunisolide HFA.

John Waugh1, Karen L Goa

  • 1Adis International Inc., Langhorne, Pennsylvannia 19047, USA. demail@adis.com

American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions
|January 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nasal high flow therapy for bronchiolitis.

Journal of paediatrics and child health·2024
Same author

Performance of artificial intelligence in 7533 consecutive prevalent screening mammograms from the BreastScreen Australia program.

European radiology·2023
Same author

Effect of Early High-Flow Nasal Oxygen vs Standard Oxygen Therapy on Length of Hospital Stay in Hospitalized Children With Acute Hypoxemic Respiratory Failure: The PARIS-2 Randomized Clinical Trial.

JAMA·2023
Same author

Cost-Effectiveness of Care Coordination for Children With Chronic Noncomplex Medical Conditions: Results From a Multicenter Randomized Clinical Trial.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2022
Same author

Hospital presentations with diabetic ketoacidosis: A retrospective review.

Australasian emergency care·2022
Same author

The effect of different service models on quality of care in the assessment of autism spectrum disorder in children: study protocol for a multi-centre randomised controlled trial.

BMC pediatrics·2022
Same journal

Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Asthma refractory to glucocorticoids: the role of newer immunosuppressants.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Delivery systems for pulmonary gene therapy.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Second-generation antihistamines in asthma therapy: is there a protective effect?

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
See all related articles

A new hydrofluoroalkane (HFA) flunisolide inhaler offers improved lung deposition and similar asthma treatment efficacy at a lower dose compared to older chlorofluorocarbon (CFC) inhalers. This HFA formulation is well-tolerated with minimal systemic effects.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Respiratory Medicine

Background:

  • Flunisolide, a synthetic corticosteroid, treats persistent asthma via metered-dose inhalers (MDIs).
  • Chlorofluorocarbon (CFC) propellants are being phased out globally due to ozone depletion.
  • A new hydrofluoroalkane (HFA) propellant formulation for flunisolide MDIs has been developed.

Purpose of the Study:

  • To evaluate the efficacy and safety of a new flunisolide HFA MDI formulation.
  • To compare the new HFA formulation with the existing flunisolide CFC MDI and placebo.
  • To assess the impact of formulation changes on aerosol properties and lung deposition.

Main Methods:

  • A randomized, double-blind, placebo-controlled, 12-week study.
  • Patients with mild to moderate asthma received flunisolide HFA (170/340 µg BID), flunisolide CFC (500/1000 µg BID), or placebo.

Related Experiment Videos

  • Aerosol particle size and lung deposition were analyzed.
  • Adrenal function and systemic effects were monitored in long-term studies.

    • Main Results:

    • Flunisolide HFA MDI produced smaller aerosol particles (1.2 µm MMAD) compared to CFC suspension (3.8 µm MMAD).
    • The HFA formulation demonstrated similar efficacy to the CFC formulation at one-third the dose.
    • Significantly greater efficacy than placebo was observed for flunisolide HFA.
    • Improved distal lung deposition was noted with the HFA MDI, featuring a redesigned built-in spacer.
    • Flunisolide HFA was well-tolerated, with no adrenal suppression and minimal systemic effects in adults and children.

    Conclusions:

    • The new flunisolide HFA MDI formulation is an effective and safe alternative to CFC-based inhalers for persistent asthma.
    • The HFA formulation offers improved lung deposition and efficacy at reduced dosages.
    • This environmentally friendly formulation supports the phase-out of ozone-depleting propellants.